Directly from EULAR 2024 - Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren's Treatment
In an interview with HCPLive, Jacques-Eric Gottenberg, MD, PhD, associated with the Department of Rheumatology at Strasbourg University Hospital, France, discusses the results of a study presented at the 2024 European Congress of Rheumatology (EULAR) evaluating the efficacy and safety of nipocalimab, an anti-neonatal Fc receptor (FcRn)monoclonal antibody, for the treatment of Sjögren’s disease. The team assessed the findings from the phase 2, multicenter, randomized, placebo-controlled, double-blind DAHLIAS trial.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
